Targeting Therapy to The Neuromuscular Junction: Proof of Concept

INTRODUCTION: The site of pathology in myasthenia gravis (MG) is the neuromuscular junction (NMJ). Our goal was to determine the ability to direct complement inhibition to the NMJ. Methods: A single-chain antibody directed against the alpha subunit of the acetylcholine receptor was synthesized (scFv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusner, Linda L, Satija, Namita, Cheng, Georgiana, Kaminski, Henry J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Main Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296224/
https://www.ncbi.nlm.nih.gov/pubmed/24037951
http://dx.doi.org/10.1002/mus.24057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296224/
https://www.ncbi.nlm.nih.gov/pubmed/24037951
http://dx.doi.org/10.1002/mus.24057

Ejemplares similares